Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)
Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq - A Canadian Study
Sponsor: Octapharma
Terminated
Study terminated as enrolled patients rolled over into a large international study in the same indication
Other terminated trials from Octapharma
Other Hemophilia A trials with similar outcome
Listed as NCT03344003, this observational or N/A phase trial focuses on Hemophilia A and remains terminated or withdrawn. Sponsored by Octapharma, it has been updated 15 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Mar 2021 — Dec 2021 [monthly]
Terminated
Status: Recruiting → Terminated
-
Jan 2021 — Mar 2021 [monthly]
Recruiting
▶ Show 10 earlier versions
-
May 2020 — Jan 2021 [monthly]
Recruiting
-
Dec 2019 — May 2020 [monthly]
Recruiting
-
Oct 2019 — Dec 2019 [monthly]
Recruiting
-
Mar 2019 — Oct 2019 [monthly]
Recruiting
-
Jan 2019 — Mar 2019 [monthly]
Recruiting
-
Aug 2018 — Jan 2019 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Not Yet Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Octapharma
For direct contact, visit the study record on ClinicalTrials.gov .